Genetic Determinants of Cardiovascular Response to Coffee Drinking

Caffeine Clinical Trial

Official title:

Genetic Determinants of Cardiovascular Response to Coffee Drinking

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01330680
• Other study ID #: C041003
• Status: Completed
• Phase: N/A
• First received: March 29, 2011
• Last updated: April 6, 2011
• Start date: September 2004
• Est. completion date: September 2010

Study information

• Verified date: March 2011
• Source: G. d'Annunzio University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Italy: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Cardiovascular and neuropsychologic effects of coffee are still debated. The precise mechanism underlying the actions of caffeine on the cardiovascular and neuropsychologic systems is incompletely understood and a considerable variability in the response to coffee drinking was observed, in part ascribable to a genetic trait.

The aim of the study is to evaluate acute cardiovascular and neuropsychologic effects of coffee and explore whether such effects are influenced by the genetic asset of caffeine metabolism (by a polymorphisms of cytochrome P450 1A2), adenosine metabolism (by polymorphisms of adenosine receptor and adenosine monophosphate deaminase) or catecholamine receptors (by polymorphisms of adrenergic receptors).

Description:

Coffee is among the most widely consumed beverages worldwide. Despite the relationship between coffee consumption and the incidence of cardiovascular disease has been studied extensively, the effects of this drink on the cardiovascular apparatus and its role as a risk factor for coronary heart disease are still debated. Moreover, the effect of coffee on attention, sleep changes, anxiety and panic disorders was studied but a great variability was observed.

Many of the known or suspected cardiovascular and neuropsychologic effects of coffee have been attributed to caffeine. The main mechanism of action of caffeine is to antagonize adenosine receptors; a secondary effect is the inhibition of phosphodiesterases, with the subsequent accumulation of cyclic adenosine monophosphate and a intensification of the effects of catecholamines.

It is also well known that there is a considerable variability in the cardiovascular and neuropsychologic response to coffee drinking, explaining the inconsistency between different effects observed in the various studies. This variability may have a genetic basis.

The aim of the study is to evaluate acute cardiovascular and neuropsychologic effects of coffee and explore whether such effects are influenced by the genetic asset of caffeine metabolism (by a polymorphisms of cytochrome P450 1A2), adenosine metabolism (by polymorphisms of adenosine receptor and adenosine monophosphate deaminase) or catecholamine receptors (by polymorphisms of adrenergic receptors).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 110
• Est. completion date: September 2010
• Est. primary completion date: December 2006
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Age between 18 and 40 years

• Males (to avoid variation due to female hormonal cycle)

• No known active ongoing disease (apparent good health)

• Non-smokers (to avoid contributory effects of nicotine or other tobacco alkaloids to caffeine effects or tolerance)

• Average coffee intake (not less than one cup/day and not greater than three cups/day)

Exclusion Criteria:

• Treatment with any drug with known activity on the adrenergic system

• Hypertension

• Therapy with sympathomimetic drugs, theophylline, alpha- or beta-blockers, any antihypertensive therapy

• Body mass index (BMI) > 30 kg/m2 (obesity)

• BMI < 18.5 kg/m2

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

Related Conditions & MeSH terms

• Caffeine

Intervention

Dietary Supplement:
• Coffee
40 mL dose of a decaffeinated preparation spiked with the addition of caffeine, at a dose of 3 mg/kg
• Decaffeinated coffee
40 mL dose of decaffeinated coffee

Locations

Country	Name	City	State
Italy	Institute of Cardiology - Center of Excellence on Aging, G. d'Annunzio University	Chieti

Sponsors (3)

Lead Sponsor	Collaborator
G. d'Annunzio University	Institute for Scientific Information on Coffee, Italian Istituto Nazionale Ricerche Cardiovascolari

Country where clinical trial is conducted

Italy, 

References & Publications (1)

1) Hartley TR, Lovallo WR, Whitsett TL. Cardiovascular effects of caffeine in men and women. Am J Cardiol 2004;93:1022-6. 2) Lopez-Garcia E, van Dam RM, Willett WC, et al. Coffee consumption and coronary heart disease in men and women: a prospective cohort study. Circulation 2006;113:2045-53. 3) Silletta MG, Marfisi R, Levantesi G, et al. Coffee consumption and risk of cardiovascular events after acute myocardial infarction: results from the GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico)-Prevenzione trial. Circulation 2007;116:2944-51. 4) Yang A, Palmer AA, de Wit H. Genetics of caffeine consumption and responses to caffeine. Psychopharmacology (Berl) 2010;211:245-57. 5) Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 2006;295:1135-41. 6) Fredholm BB. Astra Award Lecture. Adenosine, adenosine receptors and the actions of caffeine. Pharmacol Toxicol 1995;76:93-101. 7) Anderson JL, Habashi J, Carlquist JF, et al. A common variant of the AMPD1 gene predicts improved cardiovascular survival in patients with coronary artery disease. J Am Coll Cardiol 2000;36:1248-52. 8) Snapir A, Heinonen P, Tuomainen TP, et al. An insertion/deletion polymorphism in the alpha2B-adrenergic receptor gene is a novel genetic risk factor for acute coronary events. J Am Coll Cardiol 2001;37:1516-22. 9) Bengtsson K, Melander O, Orho-Melander M, et al. Polymorphism in the beta(1)-adrenergic receptor gene and hypertension. Circulation 2001;104:187-90. 10) White HL, Maqbool A, McMahon AD, et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals at risk of coronary events. A WOSCOPS substudy. Eur Heart J 2002;23:1087-92. 11) Brodde OE. Beta-1 and beta-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses. Pharmacol Ther 2008;117:1-29.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in platelet aggregation	Light transmission aggregometry (LTA) induced by ADP and apinephrine. Platelet function analyzer (PFA) by collagen-ADP and collagen-epinephrine cartridges.	From baseline to 30 minutes and 2 hours after coffee or decaffeinated alternatively	No
Primary	Change in cognitive tasks measures	Low intensity task of focused attention and choice reaction times (Categorical Search Task).; More demanding response interference tasks (Letter Flanker Task). Classic interference task (Stroop Test).	From 30 minutes until 2 hours after coffee or decaffeinated alternatively	No
Primary	Change in blood pressure		From baseline until 2 hours after coffee or decaffeinated alternatively	No
Primary	Change in heart rate		From baseline until 2 hours after coffee or decaffeinated alternatively	No
Secondary	Change in plasma caffeine concentration		From baseline to 30 minutes and 2 hours after coffee or decaffeinated alternatively	No
Secondary	Change in plasma adrenaline and noradrenaline concentration		From baseline to 30 minutes and 2 hours after coffee or decaffeinated alternatively	No